共 50 条
- [42] Use of Cinacalcet HCL (MIMPARA®/SENSIPAR®) to control mineral metabolism in patients with end-stage renal disease (ESRD) on dialysis complicated by secondary hyperparathyroidism (SHPT):: A cost-consequence analysis of Cinacalcet HCL versus standard of care (SC) NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 136 - 136
- [43] Cinacalcet Improves Control of Secondary Hyperparathyroidism in Peritoneal Dialysis: A Multicenter Study PERITONEAL DIALYSIS INTERNATIONAL, 2012, 32 (02): : 208 - 211
- [49] Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCI in hemodialysis patients with secondary hyperparathyroidism (HPT). JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 461A - 461A
- [50] Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet NEFROLOGIA, 2023, 43 (02): : 197 - 203